Copyright Reports & Markets. All rights reserved.

Global Gefitinib Sales Market Report 2021

Request for Sample of this report
Buy now

1 Gefitinib Market Overview

  • 1.1 Gefitinib Product Scope
  • 1.2 Gefitinib Segment by Type
    • 1.2.1 Global Gefitinib Sales by Type (2016 & 2021 & 2027)
    • 1.2.2 10 Tables/Box
    • 1.2.3 30 Tables/Box
    • 1.2.4 90 Tables/Box
  • 1.3 Gefitinib Segment by Application
    • 1.3.1 Global Gefitinib Sales Comparison by Application (2016 & 2021 & 2027)
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Drug Center
    • 1.3.5 Other
  • 1.4 Gefitinib Market Estimates and Forecasts (2016-2027)
    • 1.4.1 Global Gefitinib Market Size in Value Growth Rate (2016-2027)
    • 1.4.2 Global Gefitinib Market Size in Volume Growth Rate (2016-2027)
    • 1.4.3 Global Gefitinib Price Trends (2016-2027)

2 Gefitinib Estimates and Forecasts by Region

  • 2.1 Global Gefitinib Market Size by Region: 2016 VS 2021 VS 2027
  • 2.2 Global Gefitinib Retrospective Market Scenario by Region (2016-2021)
    • 2.2.1 Global Gefitinib Sales Market Share by Region (2016-2021)
    • 2.2.2 Global Gefitinib Revenue Market Share by Region (2016-2021)
  • 2.3 Global Gefitinib Market Estimates and Forecasts by Region (2022-2027)
    • 2.3.1 Global Gefitinib Sales Estimates and Forecasts by Region (2022-2027)
    • 2.3.2 Global Gefitinib Revenue Forecast by Region (2022-2027)
  • 2.4 Geographic Market Analysis: Market Facts & Figures
    • 2.4.1 North America Gefitinib Estimates and Projections (2016-2027)
    • 2.4.2 Europe Gefitinib Estimates and Projections (2016-2027)
    • 2.4.3 China Gefitinib Estimates and Projections (2016-2027)
    • 2.4.4 Japan Gefitinib Estimates and Projections (2016-2027)
    • 2.4.5 Southeast Asia Gefitinib Estimates and Projections (2016-2027)
    • 2.4.6 India Gefitinib Estimates and Projections (2016-2027)

3 Global Gefitinib Competition Landscape by Players

  • 3.1 Global Top Gefitinib Players by Sales (2016-2021)
  • 3.2 Global Top Gefitinib Players by Revenue (2016-2021)
  • 3.3 Global Gefitinib Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gefitinib as of 2020)
  • 3.4 Global Gefitinib Average Price by Company (2016-2021)
  • 3.5 Manufacturers Gefitinib Manufacturing Sites, Area Served, Product Type
  • 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Gefitinib Market Size by Type

  • 4.1 Global Gefitinib Historic Market Review by Type (2016-2021)
    • 4.1.1 Global Gefitinib Sales Market Share by Type (2016-2021)
    • 4.1.2 Global Gefitinib Revenue Market Share by Type (2016-2021)
    • 4.1.3 Global Gefitinib Price by Type (2016-2021)
  • 4.2 Global Gefitinib Market Estimates and Forecasts by Type (2022-2027)
    • 4.2.1 Global Gefitinib Sales Forecast by Type (2022-2027)
    • 4.2.2 Global Gefitinib Revenue Forecast by Type (2022-2027)
    • 4.2.3 Global Gefitinib Price Forecast by Type (2022-2027)

5 Global Gefitinib Market Size by Application

  • 5.1 Global Gefitinib Historic Market Review by Application (2016-2021)
    • 5.1.1 Global Gefitinib Sales Market Share by Application (2016-2021)
    • 5.1.2 Global Gefitinib Revenue Market Share by Application (2016-2021)
    • 5.1.3 Global Gefitinib Price by Application (2016-2021)
  • 5.2 Global Gefitinib Market Estimates and Forecasts by Application (2022-2027)
    • 5.2.1 Global Gefitinib Sales Forecast by Application (2022-2027)
    • 5.2.2 Global Gefitinib Revenue Forecast by Application (2022-2027)
    • 5.2.3 Global Gefitinib Price Forecast by Application (2022-2027)

6 North America Gefitinib Market Facts & Figures

  • 6.1 North America Gefitinib Sales by Company
    • 6.1.1 North America Gefitinib Sales by Company (2016-2021)
    • 6.1.2 North America Gefitinib Revenue by Company (2016-2021)
  • 6.2 North America Gefitinib Sales Breakdown by Type
    • 6.2.1 North America Gefitinib Sales Breakdown by Type (2016-2021)
    • 6.2.2 North America Gefitinib Sales Breakdown by Type (2022-2027)
  • 6.3 North America Gefitinib Sales Breakdown by Application
    • 6.3.1 North America Gefitinib Sales Breakdown by Application (2016-2021)
    • 6.3.2 North America Gefitinib Sales Breakdown by Application (2022-2027)

7 Europe Gefitinib Market Facts & Figures

  • 7.1 Europe Gefitinib Sales by Company
    • 7.1.1 Europe Gefitinib Sales by Company (2016-2021)
    • 7.1.2 Europe Gefitinib Revenue by Company (2016-2021)
  • 7.2 Europe Gefitinib Sales Breakdown by Type
    • 7.2.1 Europe Gefitinib Sales Breakdown by Type (2016-2021)
    • 7.2.2 Europe Gefitinib Sales Breakdown by Type (2022-2027)
  • 7.3 Europe Gefitinib Sales Breakdown by Application
    • 7.3.1 Europe 145 Sales Breakdown by Application (2016-2021)
    • 7.3.2 Europe 145 Sales Breakdown by Application (2022-2027)

8 China Gefitinib Market Facts & Figures

  • 8.1 China Gefitinib Sales by Company
    • 8.1.1 China Gefitinib Sales by Company (2016-2021)
    • 8.1.2 China Gefitinib Revenue by Company (2016-2021)
  • 8.2 China Gefitinib Sales Breakdown by Type
    • 8.2.1 China Gefitinib Sales Breakdown by Type (2016-2021)
    • 8.2.2 China Gefitinib Sales Breakdown by Type (2022-2027)
  • 8.3 China Gefitinib Sales Breakdown by Application
    • 8.3.1 China 315 Sales Breakdown by Application (2016-2021)
    • 8.3.2 China 315 Sales Breakdown by Application (2022-2027)

9 Japan Gefitinib Market Facts & Figures

  • 9.1 Japan Gefitinib Sales by Company
    • 9.1.1 Japan Gefitinib Sales by Company (2016-2021)
    • 9.1.2 Japan Gefitinib Revenue by Company (2016-2021)
  • 9.2 Japan Gefitinib Sales Breakdown by Type
    • 9.2.1 Japan Gefitinib Sales Breakdown by Type (2016-2021)
    • 9.2.2 Japan Gefitinib Sales Breakdown by Type (2022-2027)
  • 9.3 Japan Gefitinib Sales Breakdown by Application
    • 9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
    • 9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Gefitinib Market Facts & Figures

  • 10.1 Southeast Asia Gefitinib Sales by Company
    • 10.1.1 Southeast Asia Gefitinib Sales by Company (2016-2021)
    • 10.1.2 Southeast Asia Gefitinib Revenue by Company (2016-2021)
  • 10.2 Southeast Asia Gefitinib Sales Breakdown by Type
    • 10.2.1 Southeast Asia Gefitinib Sales Breakdown by Type (2016-2021)
    • 10.2.2 Southeast Asia Gefitinib Sales Breakdown by Type (2022-2027)
  • 10.3 Southeast Asia Gefitinib Sales Breakdown by Application
    • 10.3.1 Southeast Asia K Pcs Sales Breakdown by Application (2016-2021)
    • 10.3.2 Southeast Asia K Pcs Sales Breakdown by Application (2022-2027)

11 India Gefitinib Market Facts & Figures

  • 11.1 India Gefitinib Sales by Company
    • 11.1.1 India Gefitinib Sales by Company (2016-2021)
    • 11.1.2 India Gefitinib Revenue by Company (2016-2021)
  • 11.2 India Gefitinib Sales Breakdown by Type
    • 11.2.1 India Gefitinib Sales Breakdown by Type (2016-2021)
    • 11.2.2 India Gefitinib Sales Breakdown by Type (2022-2027)
  • 11.3 India Gefitinib Sales Breakdown by Application
    • 11.3.1 India Gefitinib Sales Breakdown by Application (2016-2021)
    • 11.3.2 India Gefitinib Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Gefitinib Business

  • 12.1 AstraZeneca
    • 12.1.1 AstraZeneca Corporation Information
    • 12.1.2 AstraZeneca Business Overview
    • 12.1.3 AstraZeneca Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.1.4 AstraZeneca Gefitinib Products Offered
    • 12.1.5 AstraZeneca Recent Development
  • 12.2 Qilu Pharmaceutical
    • 12.2.1 Qilu Pharmaceutical Corporation Information
    • 12.2.2 Qilu Pharmaceutical Business Overview
    • 12.2.3 Qilu Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.2.4 Qilu Pharmaceutical Gefitinib Products Offered
    • 12.2.5 Qilu Pharmaceutical Recent Development
  • 12.3 Natco Pharma
    • 12.3.1 Natco Pharma Corporation Information
    • 12.3.2 Natco Pharma Business Overview
    • 12.3.3 Natco Pharma Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.3.4 Natco Pharma Gefitinib Products Offered
    • 12.3.5 Natco Pharma Recent Development
  • 12.4 Celon Laboratories
    • 12.4.1 Celon Laboratories Corporation Information
    • 12.4.2 Celon Laboratories Business Overview
    • 12.4.3 Celon Laboratories Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.4.4 Celon Laboratories Gefitinib Products Offered
    • 12.4.5 Celon Laboratories Recent Development
  • 12.5 Hetero Drugs
    • 12.5.1 Hetero Drugs Corporation Information
    • 12.5.2 Hetero Drugs Business Overview
    • 12.5.3 Hetero Drugs Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.5.4 Hetero Drugs Gefitinib Products Offered
    • 12.5.5 Hetero Drugs Recent Development
  • 12.6 Dr Reddy's Laboratories
    • 12.6.1 Dr Reddy's Laboratories Corporation Information
    • 12.6.2 Dr Reddy's Laboratories Business Overview
    • 12.6.3 Dr Reddy's Laboratories Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.6.4 Dr Reddy's Laboratories Gefitinib Products Offered
    • 12.6.5 Dr Reddy's Laboratories Recent Development
  • 12.7 Zuventus Healthcare
    • 12.7.1 Zuventus Healthcare Corporation Information
    • 12.7.2 Zuventus Healthcare Business Overview
    • 12.7.3 Zuventus Healthcare Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.7.4 Zuventus Healthcare Gefitinib Products Offered
    • 12.7.5 Zuventus Healthcare Recent Development
  • 12.8 United Biotech
    • 12.8.1 United Biotech Corporation Information
    • 12.8.2 United Biotech Business Overview
    • 12.8.3 United Biotech Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.8.4 United Biotech Gefitinib Products Offered
    • 12.8.5 United Biotech Recent Development
  • 12.9 Panacea Biotec
    • 12.9.1 Panacea Biotec Corporation Information
    • 12.9.2 Panacea Biotec Business Overview
    • 12.9.3 Panacea Biotec Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.9.4 Panacea Biotec Gefitinib Products Offered
    • 12.9.5 Panacea Biotec Recent Development
  • 12.10 Cipla
    • 12.10.1 Cipla Corporation Information
    • 12.10.2 Cipla Business Overview
    • 12.10.3 Cipla Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.10.4 Cipla Gefitinib Products Offered
    • 12.10.5 Cipla Recent Development
  • 12.11 Glenmark Pharmaceuticals
    • 12.11.1 Glenmark Pharmaceuticals Corporation Information
    • 12.11.2 Glenmark Pharmaceuticals Business Overview
    • 12.11.3 Glenmark Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.11.4 Glenmark Pharmaceuticals Gefitinib Products Offered
    • 12.11.5 Glenmark Pharmaceuticals Recent Development
  • 12.12 Nobel Ilac Sanayii Ve Ticaret
    • 12.12.1 Nobel Ilac Sanayii Ve Ticaret Corporation Information
    • 12.12.2 Nobel Ilac Sanayii Ve Ticaret Business Overview
    • 12.12.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.12.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Products Offered
    • 12.12.5 Nobel Ilac Sanayii Ve Ticaret Recent Development
  • 12.13 Accure Labs
    • 12.13.1 Accure Labs Corporation Information
    • 12.13.2 Accure Labs Business Overview
    • 12.13.3 Accure Labs Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.13.4 Accure Labs Gefitinib Products Offered
    • 12.13.5 Accure Labs Recent Development
  • 12.14 Cadila Pharmaceuticals
    • 12.14.1 Cadila Pharmaceuticals Corporation Information
    • 12.14.2 Cadila Pharmaceuticals Business Overview
    • 12.14.3 Cadila Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.14.4 Cadila Pharmaceuticals Gefitinib Products Offered
    • 12.14.5 Cadila Pharmaceuticals Recent Development
  • 12.15 Ethypharm
    • 12.15.1 Ethypharm Corporation Information
    • 12.15.2 Ethypharm Business Overview
    • 12.15.3 Ethypharm Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.15.4 Ethypharm Gefitinib Products Offered
    • 12.15.5 Ethypharm Recent Development
  • 12.16 Flagship Biotech International
    • 12.16.1 Flagship Biotech International Corporation Information
    • 12.16.2 Flagship Biotech International Business Overview
    • 12.16.3 Flagship Biotech International Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.16.4 Flagship Biotech International Gefitinib Products Offered
    • 12.16.5 Flagship Biotech International Recent Development
  • 12.17 Globela Pharma
    • 12.17.1 Globela Pharma Corporation Information
    • 12.17.2 Globela Pharma Business Overview
    • 12.17.3 Globela Pharma Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.17.4 Globela Pharma Gefitinib Products Offered
    • 12.17.5 Globela Pharma Recent Development
  • 12.18 Jodas Expoim
    • 12.18.1 Jodas Expoim Corporation Information
    • 12.18.2 Jodas Expoim Business Overview
    • 12.18.3 Jodas Expoim Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.18.4 Jodas Expoim Gefitinib Products Offered
    • 12.18.5 Jodas Expoim Recent Development
  • 12.19 Nishchay Pharmaceuticals
    • 12.19.1 Nishchay Pharmaceuticals Corporation Information
    • 12.19.2 Nishchay Pharmaceuticals Business Overview
    • 12.19.3 Nishchay Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.19.4 Nishchay Pharmaceuticals Gefitinib Products Offered
    • 12.19.5 Nishchay Pharmaceuticals Recent Development
  • 12.20 Sichuan Xieli Pharmaceutical
    • 12.20.1 Sichuan Xieli Pharmaceutical Corporation Information
    • 12.20.2 Sichuan Xieli Pharmaceutical Business Overview
    • 12.20.3 Sichuan Xieli Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2016-2021)
    • 12.20.4 Sichuan Xieli Pharmaceutical Gefitinib Products Offered
    • 12.20.5 Sichuan Xieli Pharmaceutical Recent Development

13 Gefitinib Manufacturing Cost Analysis

  • 13.1 Gefitinib Key Raw Materials Analysis
    • 13.1.1 Key Raw Materials
    • 13.1.2 Key Raw Materials Price Trend
    • 13.1.3 Key Suppliers of Raw Materials
  • 13.2 Proportion of Manufacturing Cost Structure
  • 13.3 Manufacturing Process Analysis of Gefitinib
  • 13.4 Gefitinib Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

  • 14.1 Marketing Channel
  • 14.2 Gefitinib Distributors List
  • 14.3 Gefitinib Customers

15 Market Dynamics

  • 15.1 Gefitinib Market Trends
  • 15.2 Gefitinib Drivers
  • 15.3 Gefitinib Market Challenges
  • 15.4 Gefitinib Market Restraints

16 Research Findings and Conclusion

    17 Appendix

    • 17.1 Research Methodology
      • 17.1.1 Methodology/Research Approach
      • 17.1.2 Data Source
    • 17.2 Author List

    The global Gefitinib market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gefitinib market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

    Segment by Type
    10 Tables/Box
    30 Tables/Box
    90 Tables/Box

    Segment by Application
    Hospital
    Clinic
    Drug Center
    Other

    The Gefitinib market is analysed and market size information is provided by regions (countries). Segment by Application, the Gefitinib market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

    By Company
    AstraZeneca
    Qilu Pharmaceutical
    Natco Pharma
    Celon Laboratories
    Hetero Drugs
    Dr Reddy's Laboratories
    Zuventus Healthcare
    United Biotech
    Panacea Biotec
    Cipla
    Glenmark Pharmaceuticals
    Nobel Ilac Sanayii Ve Ticaret
    Accure Labs
    Cadila Pharmaceuticals
    Ethypharm
    Flagship Biotech International
    Globela Pharma
    Jodas Expoim
    Nishchay Pharmaceuticals
    Sichuan Xieli Pharmaceutical

    Buy now